Ubs Group Ag Regulus Therapeutics Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 184,891 shares of RGLS stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

184,891

Previous 90,147 105.1%

Holding current value

$1.47 Million

Previous $142,000 127.46%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.97 - $1.75 $91,901 - $165,802	94,744 Added 105.1%	184,891 $323,000
Q4 2024 Feb 14, 2025	BUY	$1.4 - $1.71 $84,379 - $103,063	60,271 Added 201.74%	90,147 $142,000
Q3 2024 Nov 14, 2024	BUY	$1.46 - $1.9 $15,562 - $20,252	10,659 Added 55.47%	29,876 $46,000
Q2 2024 Aug 13, 2024	BUY	$1.79 - $2.8 $33,857 - $52,962	18,915 Added 6263.25%	19,217 $34,000
Q1 2024 May 13, 2024	SELL	$1.13 - $2.88 $47 - $120	-42 Reduced 12.21%	302 $0
Q4 2023 Feb 09, 2024	SELL	$1.21 - $1.44 $77 - $92	-64 Reduced 15.69%	344 $0
Q3 2023 Nov 09, 2023	SELL	$1.27 - $1.76 $4,069 - $5,639	-3,204 Reduced 88.7%	408 $0
Q2 2023 Aug 11, 2023	BUY	$0.87 - $1.75 $1,630 - $3,279	1,874 Added 107.83%	3,612 $5,000
Q1 2023 May 12, 2023	SELL	$0.79 - $1.61 $3,099 - $6,317	-3,924 Reduced 69.3%	1,738 $1,000
Q4 2022 Feb 08, 2023	SELL	$1.17 - $1.85 $5,281 - $8,350	-4,514 Reduced 44.36%	5,662 $7,000
Q3 2022 Nov 10, 2022	BUY	$1.35 - $2.39 $2,597 - $4,598	1,924 Added 23.32%	10,176 $17,000
Q2 2022 Aug 10, 2022	BUY	$1.6 - $3.4 $13,203 - $28,056	8,252 New	8,252 $17,000

Others Institutions Holding RGLS

# of Institutions

Shares Held

53.7M

Call Options Held

104K

Put Options Held

4.1K

View Full List

About Regulus Therapeutics Inc.

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $116M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

More about RGLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account